AbbVie Tumbles 12% on Drug Reversal
March 22, 2018 at 14:38 PM EDT
AbbVie tumbled after saying it wouldn't seek fast-track approval for its long-cancer drug, Rova-T.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.